Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Pfizer expanded its hemophilia gene therapy pipeline through the SB-525 collaboration with Sangamo, viewed as a major validation of Sangamo's AAV platform and…
104-week Alta Phase 1/2 data showed sustained Factor VIII expression and reduced annualized bleeding rates at the highest dose, positioning giroctocogene…
Phase 3 AFFINE study met primary endpoint of non-inferiority and superiority on total annualized bleeding rate (1.24 vs 4.73 with FVIII prophylaxis,…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Sangamo and Pfizer entered an exclusive global collaboration for SB-525 hemophilia A gene therapy and additional cDNA AAV programs. Sangamo received $70M upfront plus eligibility for up to $475M in milestones ($300M for SB-525 development/commercialization) plus tiered double-digit royalties. Pfizer assumed responsibility for global pivotal development, manufacturing and commercialization following Phase 1/2.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / Sangamo Therapeutics, Inc. (this deal) | 2017 | $545M | — |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
← Browse all deals · How we score deals
More: 2017 deals · Pfizer Inc. deals · Hematology deals